PT97754A - Processo para a preparacao de composicoes farmaceuticas contendo pelo menos um agente inibidor da poli-(adp-ribose)-polimerase nomeadamente, uma amida aromatica, para o tratamento de infeccoes provocadas por virus - Google Patents

Processo para a preparacao de composicoes farmaceuticas contendo pelo menos um agente inibidor da poli-(adp-ribose)-polimerase nomeadamente, uma amida aromatica, para o tratamento de infeccoes provocadas por virus

Info

Publication number
PT97754A
PT97754A PT97754A PT9775491A PT97754A PT 97754 A PT97754 A PT 97754A PT 97754 A PT97754 A PT 97754A PT 9775491 A PT9775491 A PT 9775491A PT 97754 A PT97754 A PT 97754A
Authority
PT
Portugal
Prior art keywords
adp
ribose
treatment
polimerase
amid
Prior art date
Application number
PT97754A
Other languages
English (en)
Other versions
PT97754B (pt
Original Assignee
Mary Katharine Levinge Collins
Farzin Faraneh
Sydney Shall
Menoochehr Tavassoli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mary Katharine Levinge Collins, Farzin Faraneh, Sydney Shall, Menoochehr Tavassoli filed Critical Mary Katharine Levinge Collins
Publication of PT97754A publication Critical patent/PT97754A/pt
Publication of PT97754B publication Critical patent/PT97754B/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT97754A 1990-05-25 1991-05-23 Processo para a preparacao de composicoes farmaceuticas contendo pelo menos um agente inibidor da poli-(adp-ribose)-polimerase nomeadamente, uma amida aromatica, para o tratamento de infeccoes provocadas por virus PT97754B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909011833A GB9011833D0 (en) 1990-05-25 1990-05-25 Inhibition of viral infection

Publications (2)

Publication Number Publication Date
PT97754A true PT97754A (pt) 1992-04-30
PT97754B PT97754B (pt) 1998-10-30

Family

ID=10676628

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97754A PT97754B (pt) 1990-05-25 1991-05-23 Processo para a preparacao de composicoes farmaceuticas contendo pelo menos um agente inibidor da poli-(adp-ribose)-polimerase nomeadamente, uma amida aromatica, para o tratamento de infeccoes provocadas por virus

Country Status (12)

Country Link
EP (1) EP0531370B1 (pt)
JP (1) JPH05506866A (pt)
AT (1) ATE142873T1 (pt)
AU (1) AU645812B2 (pt)
CA (1) CA2082825C (pt)
DE (1) DE69122248T2 (pt)
DK (1) DK0531370T3 (pt)
GB (2) GB9011833D0 (pt)
IE (1) IE65805B1 (pt)
PT (1) PT97754B (pt)
WO (1) WO1991018591A1 (pt)
ZA (1) ZA913996B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004663A1 (en) * 1989-09-26 1991-04-18 The Regents Of The University Of California 6-amino-1,2-benzopyrones useful for treatment of viral diseases
US5484951A (en) * 1990-10-19 1996-01-16 Octamer, Incorporated 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
CA2085136C (en) * 1991-04-10 1997-03-18 Ernest Kun Method for inhibition of retroviral replication
US5482975A (en) * 1991-10-22 1996-01-09 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents
US5516941A (en) * 1991-10-22 1996-05-14 Octamer, Inc. Specific inactivators of "retroviral" (asymmetric) zinc fingers
US5877185A (en) * 1991-10-22 1999-03-02 Octamer, Inc. Synergistic compositions useful as anti-tumor agents
US5753674A (en) * 1991-10-22 1998-05-19 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents, anti-retroviral agents and anti-tumor agents
US5665720A (en) * 1992-08-07 1997-09-09 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
US5262564A (en) * 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US5783599A (en) * 1993-02-24 1998-07-21 Octamer Inc Methods of treating cancer and viral infections with 5-iodo-6-amino-and 5-iodo-6-nitroso-1 2-benzopyrones
GB9404485D0 (en) * 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US5589483A (en) * 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
AU1743997A (en) * 1996-12-20 1998-07-17 Geron Corporation Poly(adp-ribose) polymerase inhibitors to treat diseases associated with cellular senescence
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
CA2444531A1 (en) * 2001-05-08 2002-11-14 Kudos Pharmaceuticals Limited Isoquinolinone derivatives as parp inhibitors
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
UY30639A1 (es) 2006-10-17 2008-05-31 Kudos Pharm Ltd Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
BRPI0806245B1 (pt) 2007-01-10 2022-01-25 Msd Italia S.R.L. Compostos de fórmula i e seus usos
JP2010535156A (ja) 2007-08-03 2010-11-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼ阻害剤
CN101809017A (zh) 2007-09-14 2010-08-18 阿斯利康(瑞典)有限公司 酞嗪酮衍生物
EA201000948A1 (ru) 2007-12-19 2011-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы вирусной полимеразы
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
EP2346495B2 (en) 2008-10-07 2023-05-24 Kudos Pharmaceuticals Limited Pharmaceutical formulation 514
US20110015393A1 (en) 2009-07-15 2011-01-20 Astrazeneca Ab Phthalazinone compound
BR112022025134A2 (pt) 2020-06-10 2022-12-27 Metriopharm Ag 5-amino-2,3-dihidro-1,4-ftalazinadiona, composição, combinação, e, método de tratamento de uma infecção coronaviral
EP3981405A1 (en) * 2020-10-08 2022-04-13 MetrioPharm AG Compound for the treatment of coronaviral infections
EP4193994A1 (en) 2021-12-08 2023-06-14 MetrioPharm AG Combination of 5-amino-2,3-dihydro-1,4-phtalazinedione and a 6'-methoxycinchonan-9-ol for use in the treatment of coronaviral infections

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU567140B2 (en) * 1984-01-06 1987-11-12 Shionogi & Co., Ltd. Sulphonamido-benzamide derivatives
DE3715281A1 (de) * 1987-05-05 1988-11-24 Kroeger Hans Neue antiviral wirksame substanz
GB2244704B (en) * 1990-05-04 1995-05-17 Consultants Suppliers Limited Substituted benzene compounds

Also Published As

Publication number Publication date
AU645812B2 (en) 1994-01-27
DK0531370T3 (da) 1996-10-07
PT97754B (pt) 1998-10-30
CA2082825A1 (en) 1991-11-26
AU7880491A (en) 1991-12-31
EP0531370A1 (en) 1993-03-17
DE69122248T2 (de) 1997-03-06
GB2244646A (en) 1991-12-11
GB9011833D0 (en) 1990-07-18
EP0531370B1 (en) 1996-09-18
GB9111255D0 (en) 1991-07-17
DE69122248D1 (de) 1996-10-24
IE65805B1 (en) 1995-11-15
GB2244646B (en) 1994-05-25
WO1991018591A1 (en) 1991-12-12
JPH05506866A (ja) 1993-10-07
IE911784A1 (en) 1991-12-04
ZA913996B (en) 1993-01-27
ATE142873T1 (de) 1996-10-15
CA2082825C (en) 2001-10-09

Similar Documents

Publication Publication Date Title
PT97754A (pt) Processo para a preparacao de composicoes farmaceuticas contendo pelo menos um agente inibidor da poli-(adp-ribose)-polimerase nomeadamente, uma amida aromatica, para o tratamento de infeccoes provocadas por virus
BR9201848A (pt) Processo para a preparacao de particuals de virus para vacinas,vacina,e,processo para tratamento ou profilaxia de uma infeccao viral em um mamifero com necessidade dos mesmos
BR9913406A (pt) Processo de tratamento de infecção causada por pelo menos um vìrus da famìlia flaviviridae e de doença associada com a citada infecção em um hospedeiro vivo possuindo a citada infecção
PT915648E (pt) Metodos e composicoes para a modificacao selectiva de acidos nucleicos
ES2137178T3 (es) Producto sanguineo en el cual los virus han sido inactivados por medio de calor y/o detergente.
PT88930A (pt) Processo para a preparacao de novos analogos de nucleosidos e de composicoes farmaceuticas que os contem
BR9913935A (pt) Métodos de tratamento e prevenção de infecção causada por pelo menos um vìrus da famìlia dos flaviviridae e doença associada com a dita infecção em um hospedeiro vivo
ES511668A0 (es) "metodo para inactivar los virus infecciosos contenidos en una composicion enzimatica hemocoagulante".
BR9812232A (pt) Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico
ES2107609T3 (es) Polipeptidos sinteticos como inhibidores de vih-1.
DE68927025D1 (de) HIV-2-Virusvarianten
ATE165345T1 (de) Sulfonsaeurederivate zur behandlung von viruserkrankungen
PT98565A (pt) Um processo de producao de uma composicao para o tratamento da infeccao por hsv
EP0507179A3 (en) Equine herpes viruses (ehv) containing foreign dna, process for their preparation and their use as vaccines
BR9306207A (pt) Composiçao farmacéutica e processo para o tratamento de infecçao ou doença causada pelo vírus da hepatite b processo para a preparaçao da composiçao e uso de fiau ou de uma pró-droga ou metabolito do mesmo
DE69906568D1 (de) Behandlung von hämorrhagischem virusfieber mit protein c
DK0653939T3 (da) Anvendelse af en Hymenoptera-gift til fremstilling af et medikament til behandling af DNA-virusinfektioner
ES2062990T3 (es) Vacunas, que contienen la proteina f del virus del sida.
DK0531341T3 (da) Anvendelse af leukoregulin til behandling af dyr, der er inficeret med et kappevirus
DK0459176T3 (da) Oligophosphater med antiviral virkning
ATE132527T1 (de) Nicht-zurückmutierende rna-viren
PT888322E (pt) Cetonas electrofilas para tratamento de infeccoes por virus do herpes
DK549583A (da) Laegemiddel paa basis af xylosider og lyxosider af purin- og pyrimidinbaser
DE69006187D1 (de) Verwendung von Chinolyl- und Isochinolyloxazol-2-onen zur Herstellung eines Arzneimittels zur Verhinderung der Ansteckungsfähigkeit von mit Glykoproteinen umhüllten Viren.
LTIP1943A (en) Arylating agents, used in the treatment of cancerand disease caused by viral infection

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19911226

FG3A Patent granted, date of granting

Effective date: 19980706

MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20000131